Russia is only now preparing for what Kazakhstan has already successfully implemented: starting in 2027, Russian doctors will begin mass vaccination of 12–13-year-old girls against the human papillomavirus — the leading cause of cervical cancer, Interfax reports, according to infohub.kz.
According to Russian Health Minister Mikhail Murashko, teenagers will be vaccinated with a Russian-made drug. The measure is expected to dramatically reduce mortality among women and preserve their reproductive health.
He said preparatory procedures will begin in early 2027, with vaccination of 12–13-year-old girls set to start in the second half of the year.
"In any case, that is our current forecast, and today it is backed, among other things, by domestically produced products," he said at the "Mother and Child" forum.
According to the publication, teenagers are to be vaccinated with the Russian drug Tsegardeks. The head of the developer company Nanolek previously said the vaccine had already officially entered circulation. The first batch of 30,000 doses will be sent to clinics and hospitals before the end of this month.
Cervical cancer ranks second in detection frequency among Russian women aged 15 to 44. It is also the leading cause of cancer deaths among women under 44.
In Kazakhstan, vaccination of girls aged 11–13 began back in September 2024. And since May 2026, shots have also been administered to girls aged 14–17 inclusive.
In July, it was reported that more than 32,000 teenagers had received the first dose of the drug in a fairly short period.